Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab
- Autori: Passiglia, F.; Perez, A.; Listi', A.; Castiglia, M.; Musso, E.; Ancona, C.; Rizzo, S.; Alù, M.; Blasi, L.; Russo, A.
- Anno di pubblicazione: 2017
- Tipologia: Proceedings (TIPOLOGIA NON ATTIVA)
- OA Link: http://hdl.handle.net/10447/245238
Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients